Export region

Tablet coating material exported to Australia and New Zealand

TGA and Medsafe oversight, with a large complementary medicines sector alongside pharmaceutical manufacture.

Written by the Rglax Pharma technical team, who formulate and manufacture every grade named on this page at our WHO-GMP works in Tahliwal, Una (drug manufacturing licence NNZ/23/238). Reviewed 3 September 2026. Licences and certificates.

Send an export enquiry +91 98821 30484

A tablet shown half rough and half smooth — The markets we supply across Australia and New Zealand, and the route from Tahliwal. Not a statement of registration in any market.

What this region runs

Australia carries a substantial complementary medicines and supplements manufacturing sector alongside conventional pharmaceutical production, much of it producing coated tablets in volume. TGA requirements for listed and registered goods differ, and that affects what an excipient supplier has to provide.

Why our range fits it

The nutraceutical and complementary medicines side of our range is directly relevant here, and it is a segment we already supply at scale in India. Conventional pharmaceutical work runs to European and British Pharmacopoeia expectations.

What to send us

Say whether the product is a listed complementary medicine or a registered pharmaceutical, because the documentation path is not the same.

Market facts

Markets: Australia, New Zealand
Pharmacopoeia: British Pharmacopoeia and European Pharmacopoeia, with USP accepted.
Exported from: Plot No. 30, Industrial Area Tahliwal, Himachal Pradesh, India
Licence: NNZ/23/238
Compliance: WHO-GMP Compliance Unit
DMF: U.S.-DMF applied

Regulators you would be working under

TGA, Australia
Medsafe, New Zealand

Listed so you know the framework we would be supplying into. It is not a claim that we hold a registration or approval with any of them.

Grades

The 4 grades most asked for in Australia and New Zealand.

Chosen against the climate zone, the product mix and the documentation expectations of the region. Each links to its full page, with the process parameters it was developed on.

CVS-101 Moisture barrier
Moisture barrier for Amoxycillin and Clavulanate
Solvent base extra white barrier film for the most moisture sensitive combination.
Moisture barrier film coat on a solvent base, extra white, developed for Amoxycillin and Clavulanate potassium tablets. Water ingress during and after coating drives degradation in that combination, and this grade is built to hold it out.
Base ·
Non-aqueous (solvent)
Finish ·
Extra white, moisture barrier
Formulated against ·
Amoxycillin and Clavulanate potassium
AQ-ZWt10 Film coating
Aqueous film coat, extra white
Water base extra white film coat for cores that show through a standard white.
Aqueous extra white film coat developed for tablets where the core colour bleeds through a conventional white film. Calcium and Azithromycin cores are the usual cases. It gives higher opacity at the same build-up.
Base ·
Aqueous
Finish ·
Extra white, high opacity
Formulated against ·
Calcium, Azithromycin
SC-501 Seal and pre-coat
Colour or white seal coat
Pigmented sub-coat where the seal layer also has to cover the core.
Colour or white seal coat for cores that need covering as well as sealing, so the finishing film coat can be applied at a lower build-up.
Base ·
Aqueous or non-aqueous
Finish ·
White or colour
MNaq series Metallic and pearl
Metallic and pearl film coat
Solvent base metallic and pearl effect film coats, supplied in the agreed shade.
The MNaq series is a non-aqueous ready-mix film coat that gives a metallic or pearl effect finish. Each shade carries its own code, and every code runs the same way on the coater. The shade is matched and confirmed against your reference sample before the batch is released, so a repeat order reproduces the finish you approved rather than a fresh interpretation of it.
Base ·
Non-aqueous (solvent)
Finish ·
Metallic or pearl, shade on reference